Company Description
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.
The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions.
It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services.
The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers.
The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
| Country | Netherlands |
| Founded | 1986 |
| IPO Date | Jun 28, 1996 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 5,967 |
| CEO | Thierry Bernard |
Contact Details
Address: Hulsterweg 82 Venlo, 5912 PL Netherlands | |
| Phone | 31 77 355 6600 |
| Website | qiagen.com |
Stock Details
| Ticker Symbol | QGEN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001015820 |
| CUSIP Number | N72482123 |
| ISIN Number | NL0015002CX3 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thierry Bernard | Chief Executive Officer, MD and Member of Management Board |
| Dr. Roland Sackers | Chief Financial Officer, MD and Member of Management Board |
| Antonio Santos | Senior Vice President and Head of Global Operations |
| John Gilardi | Vice President of Corporate Communications and Investor Relations |
| Dr. Dominic John | Vice President of Marketing and Product Management |
| Stephany Foster | Senior Vice President and Head of Human Resources |
| Dr. Thomas Schweins | Senior Vice President of Life Science Business Area |
| Dr. Thomas Theuringer | Senior Director and Head of External Communications |
| Jean-Pascal Viola | Senior Vice President and Head of Corporate Strategy and Business Development |
| Dr. Jonathan G. Sheldon Ph.D. | Senior Vice President and Head of the QIAGEN Digital Insights Business Area |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Mar 31, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Feb 7, 2025 | 6-K | Report of foreign issuer |
| Feb 6, 2025 | SCHEDULE 13G | Filing |
| Jan 16, 2025 | 6-K | Report of foreign issuer |
| Jan 13, 2025 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | 6-K | Report of foreign issuer |